Literature DB >> 22890027

Caveolin-1 expression during the progression of pulmonary hypertension.

Jing Huang1, John H Wolk, Michael H Gewitz, Rajamma Mathew.   

Abstract

Caveolin-1 plays a pivotal role in maintaining vascular health. Progressive loss of endothelial caveolin-1 and activation of proliferative and anti-apoptotic pathways occur before the onset of monocrotaline (MCT)-induced pulmonary hypertension (PH), and the rescue of endothelial caveolin-1 attenuates PH. Recently, we reported endothelial caveolin-1 loss associated with enhanced expression of caveolin-1 in smooth muscle cells (SMC) with subsequent neointima formation in human PH. To examine whether the loss of endothelial caveolin-1 followed by an enhanced expression in SMC is a sequential event in the progression of PH, we studied rats at two and four weeks post-MCT. Right ventricular (RV) systolic pressure, RV hypertrophy, pulmonary vascular histology, and the expression of caveolin-1 and endothelial membrane proteins (platelet/endothelial cell adhesion molecule-1 [PECAM-1], both α and β subunits of soluble guanylate cyclase [sGC]), von Willebrand factor (vWF), smooth muscle α-actin, proliferative and anti-apoptotic factors (PY-STAT3 and Bcl-xL) and matrix metalloproteinase (MMP) 2 in the lungs were examined. PH was accompanied by a progressive loss of endothelial caveolin-1, activation of PY-STAT3, increased Bcl-xL expression and vascular remodeling at two and four weeks post-MCT. Loss of PECAM-1 and sGC (both subunits) paralleled that of caveolin-1, whereas vWF was well preserved at two weeks post-MCT. At four weeks post-MCT, 29% of the arteries showed a loss of vWF in addition to endothelial caveolin-1, and 70% of these arteries exhibited enhanced expression of caveolin-1 in SMC; and there was increased expression and activity of MMP2. In conclusion, MCT-induced endothelial injury disrupts endothelial cell membrane with a progressive loss of endothelial caveolin-1, and the activation of proliferative and antiapoptotic pathways leading to PH. Subsequent extensive endothelial cell damage results in enhanced expression of caveolin-1 in SMC. In addition, there is a progressive increase in MMP2 expression and activity. These alterations may further facilitate cell proliferation, matrix degradation and cell migration, thus contributing to the progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890027     DOI: 10.1258/ebm.2012.011382

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  12 in total

1.  Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.

Authors:  Jing Huang; John H Wolk; Michael H Gewitz; James E Loyd; James West; Eric D Austin; Rajamma Mathew
Journal:  World J Cardiol       Date:  2015-10-26

2.  Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Authors:  Nils P Nickel; Edda Spiekerkoetter; Mingxia Gu; Caiyun G Li; Hai Li; Mark Kaschwich; Isabel Diebold; Jan K Hennigs; Ki-Yoon Kim; Kazuya Miyagawa; Lingli Wang; Aiqin Cao; Silin Sa; Xinguo Jiang; Raymond W Stockstill; Mark R Nicolls; Roham T Zamanian; Richard D Bland; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

3.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

4.  A novel p38 mitogen-activated protein kinase/Elk-1 transcription factor-dependent molecular mechanism underlying abnormal endothelial cell proliferation in plexogenic pulmonary arterial hypertension.

Authors:  Monal Patel; Dan Predescu; Rajive Tandon; Cristina Bardita; Jennifer Pogoriler; Sangeeta Bhorade; Minhua Wang; Suzy Comhair; Anna Ryan Hemnes; Anna Ryan-Hemnes; Jiwang Chen; Roberto Machado; Aliya Husain; Serpil Erzurum; Sanda Predescu
Journal:  J Biol Chem       Date:  2013-07-26       Impact factor: 5.157

Review 5.  Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1.

Authors:  Rajamma Mathew
Journal:  World J Cardiol       Date:  2014-08-26

6.  Caveolae, caveolin-1 and cavin-1: Emerging roles in pulmonary hypertension.

Authors:  Sukrutha Chettimada; Jincheng Yang; Hyung-Geun Moon; Yang Jin
Journal:  World J Respirol       Date:  2015-07-28

7.  Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension.

Authors:  Narendra Dereddy; Jing Huang; Markus Erb; Sibel Guzel; John H Wolk; Suvro S Sett; Michael H Gewitz; Rajamma Mathew
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

8.  Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study.

Authors:  Li Huang; Li Li; Enci Hu; Guo Chen; Xianmin Meng; Changming Xiong; Jianguo He
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

9.  Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways.

Authors:  Rajamma Mathew; Jing Huang; Sanda Iacobas; Dumitru A Iacobas
Journal:  Genes (Basel)       Date:  2020-01-23       Impact factor: 4.096

10.  Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model.

Authors:  I P Temple; O Monfredi; G Quigley; H Schneider; M Zi; E J Cartwright; M R Boyett; V S Mahadevan; G Hart
Journal:  Int J Cardiol       Date:  2014-10-11       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.